Roche Holding AG
ROG
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
103,249
Roche Holding AG News & Analysis
personal-finance
The US dollar looks overvalued. Should individual investors care?
Some things are a lot more important to professional investors than everybody else.
stocks
3 cheap Wide Moat stocks in a divided industry
All but a couple of shares in this industry have sold off. Our analysts think these three high quality companies have fallen too far.
stocks
Obesity drug stocks: Where to invest now
Eli Lilly and Novo Nordisk have staged big rallies. Here’s how investors can approach this potentially huge opportunity.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,124.30 | 27.40 | -0.30% |
| CAC 40 | 8,347.20 | 0.00 | 0.00% |
| DAX 40 | 25,420.66 | 15.32 | 0.06% |
| Dow JONES (US) | 49,191.99 | 398.21 | -0.80% |
| FTSE 100 | 10,137.35 | 3.35 | -0.03% |
| HKSE | 27,037.79 | 189.32 | 0.71% |
| NASDAQ | 23,709.87 | 24.03 | -0.10% |
| Nikkei 225 | 54,413.92 | 864.76 | 1.61% |
| NZX 50 Index | 13,718.02 | 61.97 | 0.45% |
| S&P 500 | 6,963.74 | 13.53 | -0.19% |
| S&P/ASX 200 | 8,793.90 | 27.90 | -0.32% |
| SSE Composite Index | 4,179.40 | 40.65 | 0.98% |